Ana Rebeca Jaloma-Cruz

Dr. Ana Rebeca Jaloma-Cruz

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2013 in Haemophilia
Verified
Journal Article
Closed access
PDF file
HLHilda Luna-Záizar
Hilda Luna-Záizar
CBC. P. Beltrán‐Miranda
C. P. Beltrán‐Miranda
MEM. A. Esparza‐Flores
M. A. Esparza‐Flores
JSJ. Soto‐Padilla
J. Soto‐Padilla
ABA. Bergés‐García
A. Bergés‐García
AJAna Rebeca Jaloma-Cruz
Ana Rebeca Jaloma-Cruz

14 March 2007 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
JMJohanna Milena Mantilla‐Capacho
Johanna Milena Mantilla‐Capacho
CBClaudia Patricia Beltrán‐Miranda
Claudia Patricia Beltrán‐Miranda
HLHilda Luna-Záizar
Hilda Luna-Záizar
LALilia Aguilar‐López
Lilia Aguilar‐López
MEMaría Amparo Esparza‐Flores
María Amparo Esparza‐Flores
AJAna Rebeca Jaloma-Cruz
Ana Rebeca Jaloma-Cruz
Hemophilia A (HA) is one of the most common inherited bleeding disorders caused by FVIII gene mutations. Inversion of intron 22 (inv22) originates 50% of cases of severe HA and is a major risk factor for inhibitor development. Inversion of intron 1 (inv1) has been reported to occur in 2–3% of severe HA patients. We studied both inversions to determine their frequencies in Mexican patients with severe HA and to compare these data with other HA populations. The inv22 was evaluated as a risk factor for FVIII inhibitor development in severe HA patients. We studied 44 patients from 31 severe HA families for the detection of inv22 and 94 patients from 65 families to detect inv1. We used the subcycling long‐distance PCR to detect inv22 and rapid PCR in duplex reactions to detect inv1. We found a frequency of 45% for the inv22 and no inv1‐positive patients (0%). These frequencies were not statistically different from other populations, although haplotype analyses of FVIII gene and telomeric regions should be incorporated to explore population‐specific variation of inv1 frequencies. Inv22‐positive patients showed 1.88X higher risk for developing inhibitors with respect to patients carrying other severe mutations; however, this OR value was not significant. Our findings confirm inv22 as a hot‐spot for severe HA and evidence the low frequency of inv1 in a Mexican population. The non‐significant risk for developing inhibitors among inv22‐positive patients agrees with the variety of genetic and non‐genetic factors involved in such a complication. Am. J. Hematol., 2007.

1 December 2015 in Thrombosis Research
Verified
Journal Article
Closed access
HLHilda Luna-Záizar
Hilda Luna-Záizar
AGAna Isabel González-Moncada
Ana Isabel González-Moncada
EPEmily Lizbeth Padilla-López
Emily Lizbeth Padilla-López
ARAna Cristina Ramírez-Anguiano
Ana Cristina Ramírez-Anguiano
FPFermin Paul Pacheco-Moises
Fermin Paul Pacheco-Moises
AJAna Rebeca Jaloma-Cruz
Ana Rebeca Jaloma-Cruz

1 January 2016 in Genetics and Molecular Research
Verified
Journal Article
Closed access
JJJose de Jesus Lopez Jimenez
Jose de Jesus Lopez Jimenez
ÁPÁ. Porras-Dorantes
Á. Porras-Dorantes
CJC.I. Juárez-Vázquez
C.I. Juárez-Vázquez
JGJ.E. García-Ortiz
J.E. García-Ortiz
CFC.A. Fuentes-Chávez
C.A. Fuentes-Chávez
AJAna Rebeca Jaloma-Cruz
Ana Rebeca Jaloma-Cruz
Idiopathic recurrent pregnancy loss (IRPL) is defined by three or more consecutive miscarriages occurring before the twentieth week of gestation as a result of unidentified etiological factors. The results of previous studies have indicated that prothrombotic factors play a pathogenic role in early and late pregnancy. This study aimed to identify inherited prothrombotic and hypofibrinolytic risk factors in Mexican-Mestizo patients with IRPL. Fifty-six women with IRPL and 50 control women with at least two full-term pregnancies and no history of RPL were included in this case-control study. Four prothrombotic (F5 G1691A, F2 G20210A, MTHFR C677T-A1298C) and one hypofibrinolytic (PAI1 4G/5G) restricted fragment length polymorphisms were subjected to molecular analysis. In the case of hypofibrinolytic ACE Ins/Del (I/D), identification was performed by direct PCR. The independent risk correlated with the presence of polymorphisms in IRPL patients was estimated using odds ratio (OR) with a 95% confidence interval (CI). MTHFR 677TT was the most frequent prothrombotic factor in the IRPL group (23%), followed by the compound-heterozygous C677T-A1298C (16%) and heterozygous F2 20210GA (3.6%). The heterozygous ACE I/D (62%) was the main hypofibrinolytic risk factor of IRPL, followed by the homozygote PAI1 4G/4G (18%). The ACE I/D polymorphism was the only significantly different factor among the cases and controls. The dominant genetic model D/D+I/D vs I/I showed an OR (95%CI) of 2.89 (1.22-6.89) and P = 0.019 in Mexican-Mestizo women. The results of this study support an association between the ACE I/D polymorphism and IRPL risk in a Mexican population.

1 July 2018 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
HLHilda Luna-Záizar
Hilda Luna-Záizar
JGJosé Ángel González-Alcázar
José Ángel González-Alcázar
NENatalia Evangelista-Castro
Natalia Evangelista-Castro
LALilia Beatriz Aguilar-López
Lilia Beatriz Aguilar-López
SRSandra Luz Ruiz-Quezada
Sandra Luz Ruiz-Quezada
AJAna Rebeca Jaloma-Cruz
Ana Rebeca Jaloma-Cruz

1 May 2001 in Archives of Medical Research
Verified
Journal Article
Closed access
Hector Rangel-VillalobosHector Rangel-Villalobos
Hector Rangel-Villalobos
AJAna Rebeca Jaloma-Cruz
Ana Rebeca Jaloma-Cruz
LSLucila Sandoval-Ramı́rez
Lucila Sandoval-Ramı́rez
JVJesús Salvador Velarde-Félix
Jesús Salvador Velarde-Félix
Martha GallegosMartha Gallegos
Martha Gallegos
LVLuis Eduardo Figuera Villanueva
Luis Eduardo Figuera Villanueva